- Vistagen Inc VTGN announced FDA feedback regarding using the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint for future clinical studies designed to evaluate the efficacy of a treatment for the overall control of symptoms of a social anxiety disorder (SAD).
- SAD is on the rise post-COVID, impacting roughly 23.7 million people across the United States, the company told Benzinga in an email statement.
- With FDA feedback confirming the acceptable use of the LSAS as a primary efficacy endpoint, Vistagen is positioned to finalize key components of its potential marketing application-enabling development program for fasedienol for SAD.
- The company also plans to include a second LSAS-based Phase 3 study and an open-label long-term safety study in its potential NDA-enabling FEARLESS Phase 3 program for fasedienol in SAD.
- The company plans to have further protocol discussions with the FDA regarding additional dosing study(s), which the company plans to conduct in parallel with FEARLESS-1 and potentially before the commencement of the second LSAS-based Phase 3 study.
- Vistagen has decided to close the PALISADE-2 study given the expense, time, and methodological complexities involved in resuming PALISADE-2 after failed Phase 3 PALISADE-1 trial.
- Vistagen will focus resources primarily on the planning and preparation for FEARLESS-1 Phase 3 study. Topline results from the 140 subjects who completed PALISADE-2 are expected in the second half of 2023.
- Last week, the company said long-term intranasal administration of fasedienol up to four times per day in daily life was safe and well-tolerated in nearly 500 SAD patients.
- Price Action: VTGN shares are down 4.45% at $0.13 on the last check Thursday.
Loading...
Loading...
VTGNVistagen Therapeutics Inc
$2.31-0.22%
Edge Rankings
Momentum
20.54
Growth
Not Available
Quality
Not Available
Value
5.35
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
